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MaState-of-the-art drug-eluting metal stents are the gold standard for interventional treatment of coronary artery disease.
Although they overcome some disadvantages and limitations of plain balloon angioplasty and bare-metal stents, some
limitations apply, most notably a chronic local inﬂammatory reaction due to permanent implantation of a foreign
body, restriction of vascular vasomotion due to a metal cage, and the risk of late and very late stent thrombosis. The
development of biodegradable scaffolds is a new approach that attempts to circumvent these drawbacks. These devices
provide short-term scaffolding of the vessel and then dissolve, which should theoretically circumvent the side effects
of metal drug-eluting stents. Various types of these bioresorbable scaffolds are currently under clinical evaluation.
This review discusses different concepts of bioresorbable scaffolds with respect to material, design, and drug elution
and presents the most recent evidence. (J Am Coll Cardiol 2014;64:2541–51) © 2014 by the American College of
Cardiology Foundation.N ew techniques for interventional treatmentof coronary artery disease are continuouslybeing developed. Important milestones in-
clude the launch of balloon angioplasty in 1977, the
introduction of bare-metal stents in the 1980s, and
the application of drug-eluting stents (DES) since
2000. DES were widely investigated in different set-
tings, demonstrated clinical success, and entered
into clinical guidelines as the treatment of choice
for interventional revascularization of coronary ar-
tery stenosis (1,2). DES overcame disadvantages,
such as acute vessel recoil and dissection risk after
plain balloon angioplasty and decreased myocardial
infarction and target lesion revascularization (TLR)
rates compared with bare-metal stents due to
reduced neointimal tissue growth (3). Despite these
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ABBR EV I A T I ON S
AND ACRONYMS
BRS = bioresorbable
scaffold(s)
BVS = bioresorbable
vascular scaffold
CE = Conformité Européenne
DES = drug-eluting stent(s)
IVUS = intravascular
ultrasound
MACE = major adverse
cardiac event(s)
OCT = optical
coherence tomography
PCI = percutaneous
coronary intervention
PLLA = poly-L-lactic acid
TLR = target lesion
revascularization
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2542lower rate of deﬁnite very late stent throm-
bosis with the bioresorbable polymer coating
during a 4-year follow-up (8). Additionally,
improved vasomotion and endothelialization
was seen (9,10), although hard endpoints
(e.g., myocardial infarction, TLR, cardiac
death) did not differ signiﬁcantly (8,11). In
another randomized, controlled trial, no sig-
niﬁcant differences were observed in out-
comes between DES types during a 3-year
follow-up (12). Furthermore, a recent meta-
analysis revealed nonsuperiority, even infe-
riority, of DES coated with bioresorbable
polymer compared with cobalt–chromium
everolimus-eluting stents (13). In addition to
the need for more long-term data, further
challenges must be addressed to improve
preliminary results. Nevertheless, this stent
type cannot resolve long-term vessel cagingand the side effects associated with permanent
implants.
The next interventional cardiology advance may be
the introduction of bioresorbable scaffolds (BRS). The
term scaffold highlights the temporary nature of a
BRS, distinct from a stent associated with a perma-
nent implant. All resorbable scaffolds are commonly
referred to as bioresorbable, even though some are
not made of biomaterials.
The idea of dissolvable scaffolds is not new, dating
to the description of Tamai et al. (14) of the ﬁrst
successful use of a fully degradable stent in the early
1990s. However, this concept was nearly forgotten
due to the success of bare-metal stents and, later,
DES. With long-term data and the revelation of the
risks of metal stents, BRS development was reini-
tiated, resulting in a variety of devices.
MATERIAL COMPOSITION AND PROPERTIES
The optimal BRS should ensure adequate short- to
mid-term scaffolding of the previously stenosed
vessel to avoid recoil and completely dissolve after-
ward to prevent side effects. Thus, temporarily suf-
ﬁcient radial support is needed, with struts as thin as
possible. The design should warrant deliverability
and straightforward handling, ﬂexibility in different
anatomic circumstances, and integrity during
resorption. The optimal duration until full resorption
is not yet deﬁned. To achieve these goals, a consid-
erable variety of materials and designs are under
investigation.
Furthermore, the use of drug elution is inconsis-
tent. Several different substances have been applied,
and some BRS are noneluting. The current trend istoward broader use of drug elution, with mTOR
(mammalian target of rapamycin) inhibitors as
the most frequently used antiproliferative drugs in
DES.
The Central Illustration provides an overview of
different designs and characteristics of existing BRS,
with representative images in Figures 1 and 2.
POLY-L-LACTIC ACID. Different materials are used
for manufacturing BRS, with poly-L-lactic acid (PLLA)
being the most commonly used. For most existing
PLLA-based devices, strut thickness is 150 mm. A BRS
currently being developed has the thinnest struts
(100 mm) of all BRS, irrespective of composition. Ac-
cording to the manufacturer, a PLLA-based scaffold
has radial strength comparable to that of current
drug-eluting metal stents. Directly after implanta-
tion, radial strength is w1,200 mm Hg, and the
observed radial force can still be as great as 800
mm Hg after 1 year. Degradation by hydrolysis of
interlactic bonds of the long PLLA chains results in
particles that macrophages can phagocytose. The
end product is lactic acid, metabolized via pyruvate
into carbon dioxide and water through the Krebs cy-
cle (15), with complete degradation achieved in 1 to 3
years (Central Illustration). Figure 3 shows degrada-
tion over time of the BRS compared with the Xience
DES (Abbott Vascular, Santa Clara, California). PLLA-
based devices ensure radial support for w6 months.
MAGNESIUM. Magnesium, complemented by rare
earth metals to improve radial strength, is another
currently used BRS production base. The ﬁrst
magnesium-based scaffolds were uncoated and lacked
antiproliferative drug elution. The underlying idea is
that the electronegative charge that emerges during
the degradation of metal BRS is antithrombotic
(16,17). A further potential beneﬁt is its high mechan-
ical strength, making it a stent with thinner struts,
but radial strength similar to that of other bio-
resorbable scaffolds, possible. Depending on compo-
sition, degradation takes between 2 and 12 months.
The products of stent dissolution by corrosion are
inorganic salts (17). The latest generation device offers
9 to 12 months of radial support (18).
OTHER MATERIALS
A tyrosine polycarbonate–based BRS providing up to
6 months of radial support is also under investigation.
Resorption takes between 24 and 36 months. Final
products of degradation, which starts with hydrolysis
and ends with the Krebs cycle, are ethanol, water, and
carbon dioxide (19).
A BRS made of polylactic anhydride containing
2 salicylic acid molecules linked to 1 sebacic acid
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port. Degradation into salicylate, water, and carbon
dioxide is complete within w15 months (19).
POTENTIAL BENEFITS
BRS achieve successful acute revascularization of
coronary artery lesions and show reasonably low
rates of TLR and major adverse cardiac events (MACE)
during early follow-up (Central Illustration). Multiple
imaging analyses reveal beneﬁcial plaque stabiliza-
tion and sealing caused by BRS-induced remodeling
(20), although the clinical impact needs further
assessment. Due to BRS degradation, no foreign body
remains in the vessel long term. Thus, late and very
late stent thrombosis risks are potentially reduced
or eliminated, depending on resorption duration.
Total stent length is a well-known stent thrombosis
risk factor. Because BRS dissolve, this risk may be
reduced, especially in long or complex lesions and
diffuse disease, when several would be implanted
simultaneously. Additionally, the permanent com-
plete side-branch occlusion risk may decrease.
Because struts degrade, long-term uncovered stent
struts are unlikely to factor in stent thrombosis.
Incomplete endothelialization was observed for DES
as long as 40 months after implantation (7). There are
also reduced neointimal tissue growth and neo-
atherosclerosis and chronic inﬂammation risks as re-
actions to a permanent metal implant, all well-known
late and very late stent thrombosis triggers in DES.
Because the BRS coating is degradable, not durable,
another stent thrombosis stimulus is absent. Intra-
vascular ultrasound (IVUS) and optical coherence to-
mography (OCT) examinations display late lumen
enlargement in numerous patients with the Absorb
bioresorbable vascular scaffold (BVS) and DESolve
BRS (Elixir Medical Corporation, Sunnyvale, Califor-
nia) (15,21–29).
The initial mechanical ﬂexibility of some BRS may
maintain original vessel geometry better than rigid
metal stents; this would reduce their inﬂuence on
biomechanical properties and blood ﬂow. Further-
more, minor malapposition can be resolved by BRS
self-correction, and its degradation avoids long-term
malapposition (29). Incomplete stent apposition, as
observed with DES after thrombus resolution, is
also unlikely. Because there is no long-term vessel
caging, abnormal shear stress may be reduced, as
revealed by restored vasomotion (30). In contrast,
paradoxical vasoconstriction was observed after
DES implantation, most likely due to impaired endo-
thelial function (31). BRS are better suited than metal
stents for noninvasive imaging, such as coronarycomputed tomography and magnetic resonance
imaging, because they do not cause artifacts, and
follow-up is possible with these modalities. More-
over, BRS implantation might allow surgeons to
carry out anastomosis of coronary artery bypass
grafts at distal segments, and in patients who might
require multiple interventions, there will be no
interference with previously implanted DES because
side branches can sometimes be especially difﬁcult
to recross.
THE FIRST BIORESORBABLE SCAFFOLD
The Igaki-Tamai stent (Kyoto Medical Planning Co.,
Ltd., Kyoto, Japan) was the ﬁrst BRS used in humans.
This PLLA-based BRS is self-expandable when heated;
consequently, contrast dye at 80C is used for balloon
inﬂation. Expansion continues at body temperature
until dilation and vessel wall resistance reach
equilibrium. In 2000, Tamai et al. (14) reported initial
results from 15 patients in whom 25 stents were suc-
cessfully implanted. Long-term data with >10 years of
follow-up for 50 patients treated with 84 Igaki-Tamai
biodegradable stents are available (32). Interestingly,
during the ﬁrst 6 months, minimal lumen diameter
decreased and then constantly increased to 2.22 
0.56 mm at the 3-year follow-up. IVUS analysis
showed almost constant stent cross-sectional area
after 1, 2, and 3 years, whereas minimal lumen cross-
sectional area decreased from 5.44 mm2 immediately
after the procedure to 3.64 mm2 after 6 months, then
increased to 5.18 mm2 after 3 years. During the
follow-up period, a total of 14 TLRs, 1 acute scaffold
thrombosis and 1 very late scaffold thrombosis, 1
lesion-related myocardial infarction, and 1 cardiac
death were noted. Accordingly, cumulative TLR rates
per patient were 16% after 1 and 3 years, 18% after
5 years, and 28% after 10 years (32).
Despite these promising results, development
of the Igaki-Tamai biodegradable stent was dis-
continued due to 2 limitations: ﬁrst, implantation
requires an 8-French guiding catheter, and second,
the heated contrast dye may cause vessel wall injury.
A new version of the device is currently undergoing
pre-clinical evaluation.
BIORESORBABLE SCAFFOLDS CURRENTLY
AVAILABLE IN CLINICAL PRACTICE
Several BRS types are currently in development, but
only 2 have the Conformité Européenne (CE) mark
for use in coronary artery disease: the Absorb bio-
resorbable vascular scaffold (BVS) (Abbott Vascular)
and the DESolve scaffold (Elixir Medical Corporation).
CENTRAL ILLUSTRATION Results for Current Existing Bioresorbable Scaffolds
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Resorption
time
Igaki-Tamai 
Stent
Kyoto Medical 
Planning Co, Ltd, 
Kyoto, Japan
Zigzag helical 
coil
Gold radio-
paque markers 
at both ends
Self-
expandable 
when heated
Igaki-
Tamai-FiM 
50 patients
127±17 mos
Acute recoil
22 ± 7%
MLD:
2.68 ± 0.43 mm 
post-procedural; 
1.76 ± 0.74 mm 
at 6 mos; 
2.22 ± 0.56 mm 
at 3 yrs
5.44 mm2 
post-procedural; 
3.64 mm2 
at 6 mos; 
5.18 mm2 
at 3 yrs
16% at 1 year
16% at 3 yrs
18% at 5 yrs
28% at 10 yrs
50% at 10 yrs
CE mark (for 
peripheral use)
No
170
3 yrs
PLLA
Abbott Vascular, 
Santa Monica,
CA, USA
Out-of-phase 
sinusoidal 
hoops with 
links
Radiopaque 
metal markers 
at both ends
--
Acute recoil 
0.20 ± 0.21 mm
MLD: 
2.32 mm 
post-procedural; 
1.89 mm 
at 6 mos; 
= 1.76 mm
at 2 yrs
LLL:
0.43 mm
at 6 mos;
0.48 mm
at 2 yrs
Cohort A
30 patients
5 yrs
0.0% (ID)
3.4% (non-ID)
3.4% (ID)
CE mark (for coronary use); 
randomized-controlled trial 
BVS vs. DES) is currently 
enrolling patients
Everolimus
150
Up to 3 yrs
Absorb
BVS 1.0
PLLA
Abbott Vascular, 
Santa Monica,
CA, USA
In-phase
zigzag hoops, 
cross-linked by 
bridges
Radiopaque 
metal markers 
at both ends
--
Min. lumen area: 
5.45 ± 1.08 mm2 
post-procedural; 
5.12 ± 1.01 mm2 
at 6-mos; 
5.13 ± 1.25 mm2 
at 2-yrs
Mean lumen area: 
6.53 ± 1.24 mm2 
post-procedural; 
6.36 ± 1.18 mm2 
at 6-mos; 
6.85 ± 1.78 mm2  
at 24-mos
LLL: 
0.16 ± 0.18 mm 
at 6 mos; 
0.27 ± 0.20 mm 
at 2-yrs
No evidence of 
late or very late 
Cohort B
101 patients
24 mos
ABSORB Extend
250 patients
24 mos
Cohort B
6 cases (ID)
ABSORB Extend
9.0%
Cohort B
4.0%
ABSORB Extend
7.3%
Everolimus
150
Up to 3 yrs
Absorb
BVS 1.1
PLLA
Amaranth 
Medical Inc.,  
CA, USA
Zigzag hoops, 
linked by 
bridges
--
Consists of 
multiple layers
LLL: 
0.93 ± 0.41 mm
Amaranth
FiM
13 patients
6 mos
--
--
Clinical 
evaluation, 
new version 
under dev.
No
--
1−2 yrs
Amaranth
PLLA
Elixir Medical 
Corp., Sunnyvale, 
CA, USA
Tubularly 
arranged 
hoops, linked 
by bridges
2 platinum 
radiopaque 
markers
Minor 
malapposition is 
self-corrected
6.57 ± 0.68 mm2  
post-procedural; 
6.80 ± 0.85 mm2  
at 6-mos
LLL:
0.20 ± 0.10 mm
DESolve FiM
15 patients
12 mos
1 case
2 cases
Myolimus
150
1 yr
DESolve 1st 
generation
PLLA
Elixir Medical 
Corp., Sunnyvale, 
CA, USA
Tubularly 
arranged 
hoops, linked 
by bridges
2 platinum 
radiopaque 
markers
Minor 
malapposition is 
self-corrected
LLL:
0.21 ± 0.34 mm 
at 6 mos
DESolve Nx
Study 
126 patients
12 mos
1.6% at 6 mos
3.3% at 1 yr 
(both non-ID)
3.3% at 6 mos
5.7% at 1 yr
Novolimus
150
1 yr
DESolve 2nd 
generation
PLLA
Arterial 
Remodeling 
Tech., France
Creep-
resistant hinge
--
--
Acute recoil: 
2.9%
LLL: 
<0.3 mm at
3 and 6 mos
Pre-clinical 
results
ARTDIVA FiM
--
--
--
--
Clinical 
evaluation
No
--
1.5−2 yrs
ART18Z
BRS
PLLA,
PDLA
Shandong 
HuaAn Biotech., 
Co. Ltd., China
150−170
--
2 radiopaque 
markers
Radial strength 
is comparable to 
that of DES
Acute recoil: 
2.9%
LLL: 
<0.3 mm at 
3  and 6 mos
Pre-clinical 
results
--
--
30 patients 
enrolled in 
FiM study
Sirolimus
--
Xinsorb
BRS
Poly-lactic acid,
poly 
ε-caprolactone,
poly-glycolic 
acid
OrbusNeich, 
Fort Lauderdale 
FL, USA
Helically linked
double ring
Radiopaque 
markers
Dual elution
Acute recoil: 
0.66 ± 4.32%
between the 
XInsorb BRS 
and concerning 
neointimal 
growth, MLD, 
stent area
--
--
--
Pre-clinical 
evaluation
Abluminal side: 
sirolimus
Luminal: CD34+ 
antibodies
150
--
Acute
BRS
PLLA,
L-latic-co-ε-
caprolactone,
PDLA
POLY-LACTIC ACIDBasic material
Continued on the next page
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CENTRAL ILLUSTRATION Continued
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Thickness
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Target lesion 
revascularization
Major adverse 
cardiac events
Imaging 
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proliferative 
drug elution
Resorption
time
Latest generation with radiopaque markers
Electronegative charge that emerges during degradation 
process has an antithrombotic function
OTHERMAGNESIUM
Biotronik, Berlin,
Germany
4-crown design
Clinical evaluation
165
2 mos
No
PROGRESS AMS
63 patients
up to 28 mos
diameter: 
2.47 ± 0.37 mm 
post-procedural; 
1.38 ± 0.51 mm at 4 mos
Degree of stenosis: 
12.65 ± 5.53% 
post-procedural; 
48.37 ± 17.0% at 4 mos
LLL:
1.08 ± 0.49 mm at 4 mos
39.7% at 4 mos
45.0% at 12 mos
23.8% at 4 mos
26.7% at 12 mos
Magnesium and rare 
earth metals
AMS
Biotronik, Berlin,
Germany
6-crown design
Clinical evaluation
120
9–12 mos
Paclitaxel
BIOSOLVE-I
46 patients
up to 3 yrs
LLL: 
0.65 ± 0.5 at 6 mos; 
0.52 ± 0.39 mm at 12 mos
MLD: 
2.56 ± 0.35 mm 
post-procedural; 
1.95 ± 0.59 mm at 6-mos; 
2.06 ± 0.47 mm at 12 mos
7.29 ± 1.39 mm2
post-procedural;
6.49 ± 2.11 mm2
at 6-mos; 
6.40 ± 20.4 mm2
at 12 mos
2 periprocedural 
target vessel 
myocardial infarctions
4.7% at 12 mos
Magnesium and rare 
earth metals
DREAMS 1.0
Biotronik, Berlin,
Germany
6-crown design
Clinical evaluation
150
--
BIOSOLVE-||
--
--
Sirolimus
--
--
--
Magnesium and rare 
earth metals
DREAMS 2.0
Reva Medical Inc.,
San Diego, CA, USA
Slide-and-lock 
(“ratchet”)
Clinical evaluation;
CE trial ongoing
204
2–3 yrs
Paclitaxel
FiM
--
15 mos
--
--
--
Desaminotyrosine 
polycarbonate
Fully radiopaque
--
REVA BRS
Slide-and-lock 
(“ratchet”)
Clinical evaluation;
CE trial ongoing
122
2–3 yrs
Sirolimus
RESTORE
26 patients
12 mos
Acute recoil:
3.8 ± 6.7%
LLL:
0.29 ± 0.33 mm at 12 mos
--
3 cases after 12 mos
Desaminotyrosine 
polycarbonate
Fully radiopaque
--
Reva Medical Inc.,
San Diego, CA, USA
REVA ReZolve
Xenogenics Corp., 
Canton, MA, USA
Tube with 
laser-cut voids
Clinical evaluation, pre-
clinical evaluation of the 
thinner 2nd generation
200
15 mos
Sirolimus
FiM
11 patients
1.5 yrs
No evidence of
stent recoil
--
--
Poly-lactic anhydride 
containing 2 salicylic 
acid molecules linked to 
1 sebacic acid molecule
--
Polymer causes less 
Ideal BioStent
Wiebe, J. et al. J Am Coll Cardiol. 2014; 64(23):2541–51.
Various bioresorbable scaffolds (BRS) are under investigation, and an overview of the different compositions, designs, current status, and results are
presented. CE ¼ Conformité Européenne; CSA ¼ cross-sectional area; DES ¼ drug-eluting stent; FiM ¼ ﬁrst-in-man; ID ¼ ischemia driven; LLL ¼ late lumen
loss; MLD ¼ minimal lumen diameter; PDLA ¼ poly-D-lactic acid; PLLA ¼ poly-L-lactic acid.
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Ltd.) also has the CE mark, but only for peripheral
use. No devices have U.S. Food and Drug Adminis-
tration approval.
The most widely investigated bioresorbable scaf-
fold to date is the BVS. It is made of PLLA, its strut
thickness is 150 mm, and it elutes a 1:1 mixture of poly-
D,L-lactic acid and the antiproliferative drug,everolimus. Full hydrolytic degradation takes as long
as 3 years (21).
The ﬁrst-generation BVS was investigated in the
ABSORB Cohort A, a ﬁrst-in-humans trial. This pro-
spective, open-label study included 30 patients with a
single de novo coronary artery lesion. Device success
was achieved in 94% of the patients (15). During 5
years of follow-up, the MACE rate was 3.4%, owing to
FIGURE 1 Representative Images of Various Existing Scaffolds
Different materials are currently used for bioresorbable scaffold (BRS). The Igaki-Tamai stent (Kyoto Medical Planning Co., Ltd., Kyoto, Japan)
(A), the ABSORB Bioresorbable Vascular Scaffold (Abbott Vascular, Santa Clara, California) (B), and the DESolve bioresorbable scaffold (Elixir
Medical Corporation, Sunnyvale, California) (C) are all manufactured from poly-L-lactic acid. The DREAMS magnesium alloy (Biotronik, Berlin,
Germany) (D) is a metal bioresorbable vascular scaffold. The ReZolve 2 BRS (Reva Medical Inc., San Diego, California) (E) is produced on a
desaminotyrosine polycarbonate basis, and the Ideal BioStent (Xenogenics Corp., Canton, Massachusetts) (F) is composed of a salicylate
polymer and linker.
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untreated vessel (22). Furthermore, restoration of
vasomotion was demonstrated by OCT (23). A
decrease in stent minimal lumen diameter during 2
years of follow-up was also noted (23). Additional
evaluation showed BVS shrinkage due to acute recoil
in quantitative coronary angiography and late recoil
in IVUS (24,25).
Taking these ﬁndings into account, a new version,
BVS 1.1, was developed. The struts were redesigned,
leading to increased radial strength, longer radial
support, and optimized drug transfer. BVS strut
thickness was unchanged, and room-temperature
BVS storage was now possible (26). The ABSORB
Cohort B study evaluated the second-generation BVS.
During 2 years of follow-up, the overall MACE rate
was 9.0% (27). Late lumen loss in quantitative coro-
nary angiography was substantially lower than in
Cohort A. IVUS demonstrated a signiﬁcant minimal
lumen area decrease at the 6-month follow-up, which
remained almost unchanged at the 2-year follow-up.
Remarkably, the mean lumen area also decreased
initially, but then increased signiﬁcantly 2 years after
the index procedure. OCT showed a constantly
increasing scaffold area (27). In contrast, the mean
scaffold area did not change signiﬁcantly between the
post-procedural and 12-month OCT and IVUS exami-
nations in the Cohort B2 study (28). Nevertheless,there was no evidence of late or very late scaffold
recoil. Vasomotion was tested by application of either
acetylcholine or methylergonovine and subsequent
lumen measurements, which revealed restoration of
pharmacologically induced vasomotion 12 months
after the procedure (28).
ABSORB EXTEND is another international multi-
center study, including those with long lesions and
small vessels (33). Preliminary results published with
24 months of clinical follow-up of 250 patients
demonstrated a MACE rate of 7.3%, an ischemia-
driven TLR rate of 4.0%, and a stent thrombosis rate
of 0.8% (according to the Academic Research Con-
sortium possible/deﬁnitive deﬁnition) (34). A ran-
domized, controlled trial comparing BVS and DES is
currently ongoing.
The other CE-approved, commercially available
(in Europe) BRS is the DESolve scaffold (Elixir
Medical Corporation), manufactured from PLLA and
eluting a mixture of anti-inﬂammatory myolimus
and PLLA. Strut thickness is 150 mm, and >95% of
the device is resorbed after w1 year. Its advantage,
compared with other BRS, is a wider range of
expansion, with consequently reduced strut fracture
risk, and self-correction of minor malapposition.
During the 12-month follow-up period of the
multicenter DESolve ﬁrst in humans trial, 1 TLR oc-
curred between 30 days and 6 months; there were
FIGURE 2 Angiographic and Optical Coherence Tomography Imaging of the DESolve Scaffold, Absorb BVS, and ReZolve 2 BRS
Angiographic illustration of pre-implantation vessels (A–C). No residual stenoses were found via angiography after implantation of a DESolve
scaffold (Elixir Medical Corporation, Sunnyvale, California) (D), Absorb BVS (bioresorbable vascular scaffold) (Abbott Vascular, Santa Clara,
California) (E), and ReZolve 2 BRS (Reva Medical Inc.) (F). Post-implantation optical coherence tomography imaging conﬁrms adequate scaffold
positions with no evidence of strut malapposition (G to I).
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thrombosis.
The DESolve Nx study is currently investigating
a DESolve scaffold reﬁnement, including elution
of antiproliferative novolimus and a larger device
size spectrum. The MACE rate at 1-year follow-up
was 5.7% for 126 enrolled patients. Additionally,
the lumen area, assessed by OCT, IVUS, and com-
puted tomography, was almost constant during
follow-up (35). Further evaluation in the DESolve
NX II pivotal trial is ongoing. A reﬁned version,
with 100-mm strut thickness, will soon be available
commercially.
In addition to the devices carrying the CE
mark, other BRS concepts are under clinical and
pre-clinical evaluation. The Central Illustration pro-
vides an overview of different designs andcharacteristics of existing BRS, with representative
images in Figures 1 and 2.
OFF-LABEL USE AND
SPECIAL CONSIDERATIONS
Preliminary results from registries investigating pa-
tients with acute coronary syndrome and ST-segment
elevation myocardial infarction are available and
show reasonable short-term outcomes and results
comparable to those of patients treated with DES
(36,37). Data comparing BRS use in diabetic with
nondiabetic patients and diabetic patients who
underwent DES implantation found no signiﬁ-
cant differences regarding the composite endpoint
of cardiac death, target vessel myocardial infarc-
tion, and TLR at 1-year follow-up (38). However,
FIGURE 3 Degradation and Late Lumen Enlargement of the Absorb BVS Between 1 and 42 Months After Implantation and Comparison
With an Everolimus-Eluting Stent
Porcine coronary artery model photomicrographs demonstrating continuous degradation of the poly-L-lactic acid–based Absorb BVS (bioresorbable vascular scaffold)
(Abbott Vascular, Santa Clara, California), ending in almost complete scaffold strut replacement by a provisional cellular matrix after 42 months. Late lumen enlargement
can be observed compared with an everolimus-eluting stent. (Image provided by Abbott Vascular, Santa Clara, California.)
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cularization risk due to diffuse diseased vessels
and a higher in-stent restenosis and stent throm-
bosis risk (3). Hence, from a long-term perspective,
diabetic patients might beneﬁt from BRS rather
than DES.
Although BRS use for left main coronary artery
disease was described (39), because the left main
coronary artery usually has a larger vessel diameter
than other coronary arteries and BRS are only avail-
able in limited sizes and have strict expansion ranges,
its application should be limited. In contrast, BRS use
is more feasible in small vessels and with reasonable
results (40).
BRS seem attractive for treatment of in-stent
restenosis (41). Compared with drug-eluting bal-
loons, they provide short-term scaffolding, ensure
drug delivery, and do not affect vessel diameter with
another metal layer, as with DES. Indeed, BRS strut
thickness must be considered in deciding whether to
use BRS or another option.
BRS implantation for treatment of chronic total
occlusions is feasible (42) because stent length is a
predictor of in-stent restenosis, and stent thrombosis
can be avoided by device dissolution. If multiple BRS
are required, special care should be taken to minimize
overlap due to the strut thickness of currentlyavailable BRS. In addition, the feasibility of sub-
intimal tracking is thus far unclear.
Successful BRS use in bifurcations was also
described (43,44). When treating bifurcations,
simultaneous post-dilation of the main and side
branches (“kissing”) is often required to resolve stent
distortion. Due to scaffold fracture risk, post-dilation
in BRS-treated patients should be performed with a
“mini-kissing” post-dilation technique with minimal
balloon overlap (44).
Although challenging, BRS implantation is also
feasible for ostial lesions (45). Proper lesion sizing and
BRS positioning are essential to avoid malapposed
scaffold struts that protrude from the ostium because
subsequent post-dilation may cause scaffold fracture.
BRS implantation in vein grafts was also performed
(46), but vessel dimensions and a tapered shape often
limit their use.
These ﬁndings are derived from registry data and
case reports, all performed with the Absorb BVS. All
cases were highly selected, and procedures were
performed in high-volume centers experienced in
PCIs with BRS. General BRS use restrictions must
always be considered, including the presence of
heavy calciﬁcation, severe tortuosity, and the BRS
expansion ranges. Thus, BRS implantation should
currently be reserved for patients with simple lesions
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2549and, until more evidence is available, should always
be performed according to the manufacturer’s
recommendation.
CURRENT LIMITATIONS
Some possible beneﬁts of BRS are hypothetical or
only demonstrated in animal testing or small human
cohorts, for example, the impact of restoring vaso-
motion. Most data derive from small, nonrandomized
studies investigating patients with stable coronary
artery disease and de novo lesions. Hence, relatively
few patients were treated and experience in other
anatomic settings (e.g., bifurcation lesions, long
lesions, small vessels) or clinical presentations (e.g.,
acute coronary syndrome) is limited. Thus, in com-
plex lesions, intravascular imaging should support
BRS implantation.
There are practical concerns regarding strut thick-
ness, which is greater than in conventional stents and
may lead to vessel injury, nonlaminar ﬂow, platelet
deposition, and poor deliverability. Thus, mechanical
considerations seem more challenging, especially
when calciﬁcation or tortuosity are present. Regard-
less of lesion anatomy, pre-dilation is mandatory;
direct stenting is not possible. Due to pre-dilation, a
longer balloon inﬂation time, and post-dilation, if
necessary, more induced myocardial ischemia might
be associated with BRS implantation than DES. Due to
the lack of radial strength of some BRS and poor
deliverability in complex lesions, prolonged, exten-
sive, and time-consuming pre-dilation is required,
increasing the risk of pre-dilation dissections that
might require longer and/or overlapping stents. There
is an apparently increased scaffold fracture risk with
overdilation; thus, signiﬁcant BRS upsizing is
impossible. The relatively long dilation time during
deployment may also need to be reduced. Only
limited scaffold sizes are currently available, and
special facilities are needed for storage of some. Due
to these technical particularities, the total cost and
duration of PCI with a BRS may be higher than with a
conventional DES.
Thus far, the optimal duration of dual-antiplatelet
therapy in conjunction with BRS application isunclear. Although with some devices, resorption is
achieved after a relatively short time and a reduction
seems prudent, reduced shear stress from the thick
struts of current BRS may cause platelet activation.
Multiple processes, including release of active
drugs and polymer resorption, could adversely affect
metal DES. This is illustrated by the impact of ac-
quired malapposition, in the sense of defective heal-
ing, compared with the lack of stent strut apposition
at the end of the procedure. Thus, defective healing
and late adverse reactions may not be completely
avoided with BRS.
Current BRS limitations will likely be resolved in
the future. Although their advantages already
outnumber their disadvantages, large, randomized,
controlled trials are still needed.
CONCLUSIONS
Considerable progress is being made in advancing
BRS for interventional treatment of coronary artery
disease. This technique offers advantages beyond
scaffolding a stenosed vessel and may circumvent
limitations of current DES. Preliminary results
demonstrate technical feasibility and variable, partly
positive clinical outcomes. Increasing BRS experience
is resulting in a broader spectrum of indications for
their use. However, some restrictions exist, and
further reﬁnements are required. Although numerous
bioresorbable stent devices are designed to achieve
outcomes superior to state-of-the-art metal DES, for
many, current results are inferior with respect to de-
vice success, recoil, MACE, lumen areas, and TLR.
More randomized clinical data will be required to
determine whether this new technology’s theoretical
advantages will outweigh its limitations.
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